



Ocular Therapeutix™ to Present at Oppenheimer 25th Annual Healthcare Conference

December 2, 2014

BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 2, 2014-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11, 2014 at 3:20 p.m. Eastern Time at the Crowne Plaza Hotel in New York City.

The audio-only presentation will be accessible live on Ocular Therapeutix's website at investors.ocutx.com under Investor Events and will be available for 90 days following the presentation. A copy of the investor presentation will also be made available upon written request.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Source: Ocular Therapeutix, Inc.

Investors:

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

bsmith@ocutx.com

or

Burns McClellan on behalf of Ocular Therapeutix

Kimberly Minarovich, 212-213-0006

kminarovich@burnsmc.com

or

Media:

Scott Corning

Vice President of Sales and Marketing

scorning@ocutx.com